A B S T R A C T Previous studies from this laboratory have suggested a role for cell-mediated immunity in host defense against Legionella pneumophila. In this paper, cell-mediated immunity to L. pneumophila in patients recovered from Legionnaires' disease was studied by examining patient mononuclear cell responses to L. pneumophila antigens. Patient mononuclear cells were assayed both for their capacity to respond to L. pneumophila antigens with the production of cytokines that activate monocytes, as measured by monocyte inhibition of L. pneumophila multiplication, and for their capacity to respond with proliferation, as measured by [3H]thymidine incorporation.
INTRODUCTION
Legionella pneumophila, the etiologic agent of Le- gionnaires' disease, is a facultative intracellular bacterial parasite (1) . The bacterium multiplies intracellularly in human monocytes and human alveolar macrophages, and, under tissue culture conditions, multiplication is exclusively intracellular (1, 2) .
Previous studies from this laboratory have examined the role of humoral immunity in Legionnaires' disease. These have demonstrated that virulent L. pneumophila grown in vivo are resistant to three potential functions of antibody and complement relevant to host defense (3, 4) . First, L. pneumophila are completely resistant to killing by human complement, even in the presence of high-titer human or rabbit anti-L. pneumophila antibody (3) . Second, L. pneumophila are highly resistant to killing by human phagocytes even in the presence of high-titer antibody and complement; although antibody and complement markedly promote the phagocytosis of L. pneumophila by human polymorphonuclear leukocytes and monocytes, these phagocytes kill only 0.5 log of an inoculum of L. pneumophila under optimal conditions (3, 4) . Third, L. pneumophila pretreated with antibody and complement and then incubated with monocytes in the presence of these humoral components multiply in monocytes at as rapid a rate as when they enter monocytes in the absence of antibody (4) . These studies indicated that humoral immunity does not play a primary role in host defense against L. pneumophila.
Another study has demonstrated that activated human monocytes inhibit the intracellular multiplication of L. pneumophila (5) ; the monocytes were activated with cell-free supernatants or cytokines generated by blood mononuclear cells stimulated with the plant mitogen concanavalin A (Con A).' This study indicated that cell-mediated immunity likely plays an important role in host defense against Legionnaires' disease.
This study examines the role of cell-mediated immunity in Legionnaires' disease. The study demonstrates (a) that patients recovered from Legionnaires' disease have circulating mononuclear cells sensitized to L. pneumophila antigens and (b) that in response to L. pneumophila antigens, patient mononuclear cells both proliferate and generate cytokines capable of activating normal human monocytes such that they inhibit the intracellular multiplication of L. pneumophila. METHODS Patients and nonpatients. All patients were adults from the New York City area who had had well-documented cases of Legionnaires' disease diagnosed by specialists in infectious diseases (Table I) . Patients were studied 4-20 mo after they had fully recovered from Legionnaires' disease. Adults from the New York City area who were not known to have ever had Legionnaires' disease or an L. pneumophila infection and who had anti-L. pneumophila antibody titers of <1:64 (the threshold level of significance) by the indirect fluorescent antibody (IFA) assay (6) served as controls (nonpatients). In addition, two persons from the New York City area with tuberculoid leprosy were studied; both had no known history of Legionnaires' disease and both had anti-L. pneumophila IFA titers of <1:64. Serum IFA titers to L. pneumophila Philadelphia 1 were measured on all persons participating in this study by Mr. Austin Swaby, Mrs. Remonia Clarke and Ms. Helen Kravetz at the New York City Department of Health. All patients who participated in this study did so with the approval of their personal physicians. Informed written consent was obtained from all patients and nonpa-'Abbreviations used in this paper: CFU, colony-forming units; Con A, concanavalin A; IFA, indirect fluorescent antibodv assay.
tients. All patients were seen and blood specimens obtained at The Rockefeller University Hospital outpatient clinic (New York).
Six of the seven patients had evidence of infection with serogroup 1 L. pneumophila (Table I) ; all six had significant (.1:64) serum IFA titers to L. pneumophila Philadelphia 1 (a serogroup 1 organism) at the time they were studied. The serum of the seventh patient (patient C) was tested only to combined L. pneumophila serogroups 1-4 at the time of his illness; 4 mo later, when he was studied, his serum did not have a significant IFA titer to L. pneumophila Philadelphia 1.
Media. Egg yolk buffer, with or without 1% bovine serum albumin, and RPMI 1640 medium were prepared or obtained as described previously (1) 12 ,000 g for 10 min at 4°C. In a recently published study of this strain of L. pneumophila, IFA titers of human serum obtained against formalin-killed L. pneumophila were found to be highly correlated with IFA titers obtained against heat-killed L. pneumophila, indicating that antigenic determinants of L. pneumophila measured in this assay are well maintained with formalin treatment (9) .
Human blood mononuclear cells. Heparinized venous blood was obtained from patients and nonpatients and the blood mononuclear cell fraction was separated by centrifugation over a Ficoll-sodium diatrizoate solution as previously described (1 with several patients, maximal activation was obtained with 20-40% supernatants.
Optimal conditions for production of maximally potent supernatants. The optimal length of time to incubate patient mononuclear cells with formalinkilled L. pneumophila to generate maximally potent supernatants was studied next. Six different supernatants were prepared from each of two patients by incubating their mononuclear cells with 5 X 108 formalinkilled L. pneumophila 0-10 d. These supernatants were then tested for their capacity to activate monocytes as described above. In this study, monocytes were incubated with 20% supernatants and supernatant controls (Fig. 2) .
Supernatants generated by incubation of patient mononuclear cells with formalin-killed L. pneumophila for 4 d were maximally potent, i.e., L. pneumophila multiplication was maximally inhibited by monocytes treated with 4-d supernatants. In all subsequent experiments, 4-d supernatants were used.
The optimal number of formalin-killed L. pneumophila with which to incubate patient mononuclear cells in order to generate maximally potent supernatants was studied next. Six different sets of supernatants and supernatant controls were prepared from each of two patients by incubating their mononuclear cells with 5 X 103-5 X 108 formalin-killed L. pneumophila/ ml. Supernatants generated with 5 X 106, 5 X 107, and 5 x 108 formalin-killed L. pneumophila/ml were maximally potent (Fig. 3 ), supernatants generated with 5 X 105 organisms/ml were intermediate in potency, and supernatants generated with 5 X 103 and 5 X 104 organisms/ml were inactive (data not shown). This dose response paralleled that obtained in the mononuclear cell proliferation assay, as measured by [3H]thymidine incorporation, discussed below (Table II) .
In other experiments, supernatants generated in flatbottomed wells were compared with supernatants generated in cone-shaped wells; in cone-shaped wells, leukocytes and bacterial particles settled to the tip of the cone and cell-cell contact was greatly increased. Supernatants generated in flat-bottomed and cone-shaped wells were equivalent in potency (data not shown).
Comparison of patient L. pneumophila-and Con A-induced mononuclear cell supernatants. L. pneumophila-induced supernatants were compared with Con A-induced supernatants prepared from the same patient at the same time. Con A supernatants were collected after 2 d rather than 4 d of incubation with mononuclear cells because, in earlier studies, 2-d Con A supernatants were maximally potent (4). Fig. 3 , are representative. These results may indicate that, at the time of the study, the proportion of circulating lymphocytes in these patients sensitized to L. pneumophila antigens was less than the proportion of circulating lymphocytes subject to stimulation by the nonspecific mitogen Con A.
Comparison of patient and nonpatient supernatants. The experiments presented thus far show that mononuclear cells from patients recovered from Le- gionnaires' disease respond to L. pneumophila antigens with the production of cytokines capable of activating monocytes. Whether patient mononuclear cells differ in this respect from nonpatient mononuclear cells was now examined by preparing supernatants and supernatant controls from two patients (A and B) and two nonpatients (A and B) and testing them at the same time (Fig. 4) .
The patient supernatants resulted in greater monocyte inhibition of L. pneumophila multiplication than the nonpatient supernatants (Fig. 4) (Fig. 4) .
Thus, in both assays, patient mononuclear cells showed enhanced responses to L. pneumophila antigens in comparison with age-and sex-matched nonpatient controls.
Comparison of mononuclear cells from patients recovered from Legionnaires' disease with mononuclear cells from patients with tuberculoid leprosy for capacity to respond to L. pneumophila and M. leprae antigens. The specificity of mononuclear cell responses to L. pneumophila antigens was further examined. Mononuclear cells were obtained from two patients recovered from Legionnaires' disease and from two patients under treatment for tuberculoid leprosy, and the responses of these cells to L. pneumophila and M. leprae antigens were compared. The patients were not matched for age and sex and the mononuclear cells were not collected on the same day as in the above study; however, in the case of each individual patient, the mononuclear cell supernatants to L. pneumophila and M. leprae antigens were prepared and tested and the mononuclear cells assayed for proliferation at the same time under the same conditions.
In both the mononuclear proliferation assay (Table  IVA) and the assay for monocyte activating cytokines (Table IVB) , mononuclear cells from patients recovered from Legionnaires' disease responded more strongly to L. pneumophila antigens than to M. leprae antigens, whereas mononuclear cells from patients with tuberculoid leprosy responded more strongly to M. leprae antigens than to L. pneumophila antigens.
DISCUSSION
These experiments show that cell-mediated immunity develops in patients with Legionnaires' disease. Patients recovered from Legionnaire's disease have circulating peripheral blood mononuclear cells sensitized to L. pneumophila antigens; remarkably, such cells are present many months and in one case nearly 2 yr after full recovery from Legionnaires' disease. In some cases, mononuclear cell responses to L. pneumophila persisted even though antibody titers to the same L. pneumophila strain had fallen to or below the threshold level of significance.
The conceptual basis for the experiments in this paper derive in large part from studies of acquired cellmediated immunity to infection by intracellular bacteria that were conducted by Chase and Lurie in the 1940s, Mackaness (10) demonstrated that cutaneous delayed-type hypersensitivity to tuberculin was transferable by specifically sensitized lymphoid cells and not by serum. Lurie (11) pointed out the importance of macrophages in immunity by demonstrating that macrophages harvested from vaccinated animals have an enhanced capacity to inhibit multiplication of tubercle bacilli. Mackaness (12) (14) and North (15) In this study, mononuclear cell proliferation in response to antigens correlated with the production of monocyte-activating cytokines in response to these antigens. Both mononuclear cell responses were higher in patients recovered from Legionnaires' disease than in nonpatients (Table III) ; moreover, in patients with either Legionnaires' disease or tuberculoid leprosy, both mononuclear cell responses were higher to the relevant than irrelevant antigen (Table IV) . These two mononuclear cell responses have also been highly correlated in studies of other patients in this laboratory. For example, mononuclear cells from patients with lepromatous leprosy fail to respond to M. leprae with either mononuclear cell proliferation or the production of monocyte-activating cytokines, whereas mononuclear cells from patients with tuberctloid leprosy respond strongly in both assays (manuscript in preparation).
The assays described in this paper have general applicability for the study of monocyte and mononuclear cell effector functions in selected patients. These assays may be used to study (a) the capacity of a patient's mnonocytes to be activated to an antimicrobial potential with a standardized preparation of cytokines (e.g., Con A-induced cytokines from normal mononuclear cells) and (b) the capacity of a patient's mononuclear cells to generate such monocyte-activating cytokines in response to a mitogen or antigen. The first assay requires only 9 X 106 mononuclear cells to test monocytes to a single cytokine preparation and its control (e.g., Con A-induced supernatant and supernatant control) in triplicate; this allows for six monocyte monolayers (initially from 1.5 
